15 papers in the library · 293 citations · publishing 1975-2026
May 1, 2026 David A. Gorelick
Despite its theoretically self-limiting nature, 20% of substance-induced psychosis cases remained on antipsychotics at three years. Up to one-third convert to a primary psychotic disorder within year one; post-conversion antipsychotic use reaches 75%. Younger age, female sex, mood disorder or ADHD, and log-term sick leave or disability predict higher antipsychotic continuation rates in...
August 29, 2025 David A. Gorelick
The prevalence of cannabis-induced psychosis has increased substantially, possibly due to higher cannabis potency and greater use. Antipsychotic medication reduced hospitalization risk by 25% for psychosis, 25% for substance use disorders, and 50% for medical conditions. For psychosis-related hospitalization, long-acting injectable aripiprazole or olanzapine reduced risk by 75%—twice as...
May 28, 2025 David A. Gorelick
Current evidence remains insufficient to support the use of psychedelics for substance use disorders in routine clinical practice. Psilocybin has the most supportive data for alcohol use disorder, though it is of moderate quality. The evidence quality is generally low, with significant risk of bias due to poor blinding. Only half of identified studies were RCTs, with 44% conducted over 50 years...
April 23, 2024 David A. Gorelick
Psilocybin shows promise for treatment-resistant depression, with rapid onset and long-lasting effects. Psilocybin treatment currently involves extensive psychotherapy sessions, which may limit accessibility and increase costs. The efficacy of psilocybin without concurrent psychotherapy is unknown. Long-term safety risks of psilocybin treatment remain uncertain.
Journal of Applied Toxicology November 2016 Rebecca L Hartman, Timothy L Brown, Gary Milavetz et al.
Although evidence suggests cannabis impairs driving, its driving-performance effects are not fully characterized. We aimed to establish cannabis' effects on driving longitudinal control (with and without alcohol, drivers' most common drug combination) relative to psychoactive ∆(9) -tetrahydrocannabinol (THC) blood concentrations. Current occasional (≥1×/last 3 months, ≤3 days per week) cannabis...
Journal of Analytical Toxicology March 4, 2015 Nathalie A. Desrosiers, Johannes G. Ramaekers, Émeline Chauchard et al. 136 citations
Δ9-Tetrahydrocannabinol (THC), the primary psychoactive constituent in cannabis, impairs psychomotor performance, cognition and driving ability; thus, driving under the influence of cannabis is a public safety concern. We documented cannabis' psychomotor, neurocognitive, subjective and physiological effects in occasional and frequent smokers to investigate potential differences between these...
Drug and Alcohol Dependence November 1, 2014 Marisol S. Castaneto, David A. Gorelick, Nathalie A. Desrosiers et al.
Synthetic cannabinoids (SC) are a heterogeneous group of compounds developed to probe the endogenous cannabinoid system or as potential therapeutics. Clandestine laboratories subsequently utilized published data to develop SC variations marketed as abusable designer drugs. In the early 2000s, SC became popular as "legal highs" under brand names such as Spice and K2, in part due to their ability...
The American Journal of Drug and Alcohol Abuse January 2012 Robert S. Goodwin, Michael H Baumann, David A. Gorelick et al.
The endocannabinoid system modulates the hypothalamic-pituitary-adrenal (HPA) axis, but the effect of cannabinoid type 1 (CB1) receptor antagonism following chronic CB1 receptor stimulation in humans is unknown. To evaluate effects of the CB1 receptor antagonist rimonabant on the HPA axis in cannabis-dependent individuals. Fourteen daily cannabis smokers received increasingly frequent 20 mg...
Journal of Clinical Psychopharmacology October 2011 David A. Gorelick, Robert S. Goodwin, Eugene Schwilke et al.
Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ⁹-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis dependence while residing on a closed research unit. On the ninth...
Therapeutic Drug Monitoring May 21, 2008 Erin A Kolbrich, Robert S. Goodwin, David A. Gorelick et al. 127 citations
This study examines the plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and metabolites 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-methylenedioxyamphetamine (MDA), and 4-hydroxy-3-methoxyamphetamine (HMA) in young adults for up to 143 hours after drug administration. Seventeen female and male participants (black, white, and Hispanic) received placebo, low (1.0 mg/kg),...
Psychopharmacology November 2007 Marilyn A. Huestis, Susan J Boyd, Stephen J Heishman et al.
A single 90-mg dose of the cannabinoid CB1 receptor antagonist rimonabant attenuates effects of smoked cannabis in humans. The objective of this study is to evaluate whether repeated daily 40-mg doses of rimonabant can attenuate effects of smoked cannabis to the same extent as a single higher (90 mg) dose. Forty-two male volunteers received one of three oral drug regimens in a randomized,...
American heart journal March 2006 David A. Gorelick, Stephen J Heishman, Kenzie L Preston et al.
Animal studies suggest that cannabinoid CB1 receptors play a role in regulating blood pressure (BP). In human studies, activation of CB1 receptors by cannabis or its active ingredient, Delta9-tetrahydrocannabinol (THC), has modest and inconsistent effects on BP. We evaluated this phenomenon in 63 male cannabis smokers (mean [SD] age 27.7 +/- 5.4 years, 70% African American, 10.3 +/- 5.9 years...
Psychopharmacology December 1, 1979 Robert J. Sbordone, Joseph A. Wingard, David A. Gorelick et al. 16 citations
Pairs of male Sprague-Dawley rats were administered mescaline, lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), 3,4-dimethoxyphenylethylamine (DMPEA), or 5-hydroxydopamine (5-OHDA) IP prior to being placed in a shock-elicited aggression situation. When foot shock was delivered, controls struck each other with their forepaws, but never engaged in either biting or...
Psychopharmacology 1977 David A. Gorelick, Wagner H. Bridger 9 citations
The effects of mescaline hydrochloride (4.95-79.2 mg/kg i.p.) and its non-hallucinogenic analogue 3,4-dimethoxyphenylethylamine hydrochloride (DMPEA) (12.5-100 mg/kg i.p.) on shock avoidance in a shuttlebox were studied in male Long-Evans rats trained to high (above 88%, good performers) or low (below 6%, poor performers) stable base-line avoidance rates. In good performers, mescaline and DMPEA...
Psychopharmacology 1975 David A. Gorelick, Wagner H. Bridger 5 citations
This experiment is related to the hypothesis of Bridger and of Wray that hallucinogens have facilitatory effects on animal behavior when stress is part of the experiment and have disruptive effects otherwise. Male Long-Evans rats were trained to high (above 89%), stable base line rates of shuttlebox avoidance, then given each of four treatments at 6-day intervals after returning to base line...